Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 20/20 | 0.80 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.55 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.55 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.55 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.55 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20774986 | 0.93 | GABRA5 (0.69) | GABRA5GABRG2GABRB3GABRA1GABRA3 | |
| SCHEMBL14877261 | 0.89 | GABRA5 (0.80) | GABRA5 | |
| SCHEMBL2931461 | 0.89 | GABRA5 (1.00) | GABRA5 | |
| SCHEMBL14876997 | 0.87 | GABRA5 (0.77) | GABRA5 | |
| SCHEMBL20778894 | 0.84 | GABRA5 (0.57) | GABRA5 | |
| SCHEMBL22150531 | 0.84 | GABRA5 (0.57) | GABRA5GABRG2GABRB3GABRA1GABRA3 | |
| SCHEMBL2924414 | 0.83 | GABRA5 (0.78) | GABRA5GABRG2GABRB3GABRA1GABRA3 | |
| SCHEMBL14876821 | 0.81 | GABRA5 (0.77) | GABRA5 | |
| SCHEMBL28414654 | 0.81 | GABRA5 (0.70) | GABRA5GABRG2GABRB3GABRA1GABRA3 | |
| SCHEMBL2922234 | 0.79 | GABRA5 (1.00) | GABRA5GABRG2GABRB3GABRA1GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3675845-B1 | NOVEL GAMMA AMINOBUTYRIC ACID TYPE A RECEPTOR MODULATORS FOR MOOD DISORDERS | UNIV MARYLAND (US) | 2024-07-17 | — | — | EP | claimed |
| US-20220396572-A1 | Deuterated Alpha5 subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatment for Depression and Mood Disorders | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-12-15 | — | — | US | claimed |
| WO-2019046300-A9 | NOVEL GAMMA AMINOBUTYRIC ACID TYPE A RECEPTOR MODULATORS FOR MOOD DISORDERS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-10-15 | — | — | WO | claimed |
| EP-3675845-A1 | NOVEL GAMMA AMINOBUTYRIC ACID TYPE A RECEPTOR MODULATORS FOR MOOD DISORDERS | University of Maryland, Baltimore (US) | 2020-07-08 | — | — | EP | claimed |
| US-20200199119-A1 | Deuterated Alpha5 subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatment for Depression and Mood Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-06-25 | — | — | US | claimed |
| WO-2019046300-A1 | NOVEL GAMMA AMINOBUTYRIC ACID TYPE A RECEPTOR MODULATORS FOR MOOD DISORDERS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2019-03-07 | — | — | WO | claimed |
| EP-2768827-B1 | PROCESS FOR THE PREPARATION OF ISOXAZOLYL-METHOXY-NICOTINIC ACIDS | HOFFMANN LA ROCHE (CH) | 2016-11-23 | — | — | EP | claimed |
| EP-2768827-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLYL-METHOXY-NICOTINIC ACIDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-27 | — | — | EP | claimed |
| US-8604062-B2 | Process for the preparation of isoxazolyl-methoxy nicotinic acids | HOFFMAN-LA ROCHE INC. (US) | 2013-12-10 | — | — | US | claimed |
| US-20130102778-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLYL- METHOXY NICOTINIC ACIDS | HOFFMANN-LA ROCHE INC. (US) | 2013-04-25 | — | — | US | claimed |
| WO-2013057123-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLYL-METHOXY-NICOTINIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-25 | — | — | WO | claimed |
| EP-3675845-B1 | NOVEL GAMMA AMINOBUTYRIC ACID TYPE A RECEPTOR MODULATORS FOR MOOD DISORDERS | UNIV MARYLAND (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-3675845-B1 | NOVEL GAMMA AMINOBUTYRIC ACID TYPE A RECEPTOR MODULATORS FOR MOOD DISORDERS | UNIV MARYLAND (US) | 2024-07-17 | — | — | EP | disclosed |
| US-11897875-B2 | Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type a receptors as fast acting treatment for depression and mood disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2024-02-13 | — | — | US | disclosed |
| US-20220396572-A1 | Deuterated Alpha5 subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatment for Depression and Mood Disorders | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-12-15 | — | — | US | disclosed |
| US-8604062-B2 | Process for the preparation of isoxazolyl-methoxy nicotinic acids | HOFFMAN-LA ROCHE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130172329-A1 | NOVEL SOLID FORMS | HOFFMANN-LA ROCHE INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130102778-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLYL- METHOXY NICOTINIC ACIDS | HOFFMANN-LA ROCHE INC. (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2013057124-A1 | SOLID FORMS OF 1,L-DIOXO-4-THIOMORPHOLINYL)-[6-[[3(4-FLUOROPHENYL)-5-METHYL-4-ISOXAZOLYL]METHOXY]-3-PYRIDINYL]-METHANONE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013057123-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLYL-METHOXY-NICOTINIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199119-A1 | Deuterated Alpha5 subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatment for Depression and Mood Disorders | GABRA5, GABRA4, GABRA1 | GABRA5 1/4885GABRG2 15/4885GABRB3 13/4885 |
| US-20130172329-A1 | NOVEL SOLID FORMS | F12, SLC10A1, CYP2F1 | GABRA5 3197/4885GABRG2 3630/4885GABRB3 3470/4885 |
| US-20130102778-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLYL- METHOXY NICOTINIC ACIDS | NAPRT, CHRNA1, CHRM1 | GABRA5 151/4885GABRG2 512/4885GABRB3 367/4885 |
| US-20220396572-A1 | Deuterated Alpha5 subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatment for Depression and Mood Disorders | GABRA5, GABRA4, GABRA1 | GABRA5 1/4885GABRG2 15/4885GABRB3 13/4885 |
| US-11897875-B2 | Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type a receptors as fast acting treatment for depression and mood disorders | GABRA5, GABRA4, GABRA1 | GABRA5 1/4885GABRG2 15/4885GABRB3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.